Novel transcript, sense intronic to CCDC91 (lncRNA)

ENSG00000273989, also designated as "novel transcript, sense intronic to CCDC91," refers to a long non-coding RNA (lncRNA) discovered within the intronic region of the CCDC91 gene. This transcript is not a protein-coding gene and does not represent a classic therapeutic target such as a receptor, enzyme, or transporter[2][1]. Instead, it acts as a functional lncRNA implicated in regulating osteogenic differentiation through a competitive endogenous RNA (ceRNA) mechanism: the novel CCDC91 isoform "sponges" microRNA MIR890, thereby modulating the expression of RUNX2, a master transcription factor for osteogenic differentiation. Its specific upregulation is associated with the risk of developing ossification of the posterior longitudinal ligament of the spine (OPLL), a disorder characterized by abnormal bone formation in spinal ligaments[1]. The transcript appears to have cell type–specific expression and plays a role in gene regulatory networks relevant to bone biology. There are no known drugs that interact directly with this lncRNA, and it is not established as a therapeutic target in current biomedical literature. Existing evidence suggests it could serve as a biomarker for disease risk, though more validation is needed[1][2]. Notes: - This entry is *not* a canonical therapeutic target as per standard drug discovery definitions. - The transcript has a defined molecular mechanism as a lncRNA and acts biologically via transcriptional and post-transcriptional regulation. - No direct drug interactions, safety concerns, or established biomarkers beyond research-level association with OPLL are reported. - Aliases and names may change as the field recognizes and annotates this lncRNA more precisely.

Other names

ENSG00000273989CCDC91-sense intronic lncRNANovel CCDC91 isoform